CLRB - Cellectar Biosciences Inc

https://www.cellectar.com

Momentum: Bearish

Recent News

Cellectar Biosciences to Participate in Multiple Upcoming Medical Meetings and Industry Conferences in September

GlobeNewswire • 1 week, 3 days ago • score: -0.02

FLORHAM PARK, N.J., Sept. 05, 2025 ( GLOBE NEWSWIRE ) -- Cellectar Biosciences, Inc. ( NASDAQ: CLRB ) , a late-stage clinical biopharmaceutical company focused on the discovery and development of drugs for the treatment of cancer, today announced that Jarrod Longcor, chief operating officer at ...

Neutral

Cellectar Biosciences to Report Second Quarter Financial Results and Host a Conference Call on Thursday, August 14, 2025

GlobeNewswire • 1 month, 1 week ago • score: -0.02

FLORHAM PARK, N.J., Aug. 07, 2025 ( GLOBE NEWSWIRE ) -- Cellectar Biosciences, Inc. ( NASDAQ: CLRB ) , a late-stage clinical biopharmaceutical company focused on the discovery, development and commercialization of drugs for the treatment of cancer, today announced that the Company will report ...

Interval:

EMA1: EMA2:

AI Tools

Key Metrics

Trend: Downtrend

Source: Snapshot

Cellectar Biosciences, Inc., a clinical biopharmaceutical company, focuses on the discovery, development and commercialization of drugs for the treatment of cancer. The company is headquartered in Florham Park, New Jersey.

52W High

$67.50

52W Low

$4.11

MA Status:

50D: Below 200D: Below

Beta (~1 neutral, <0.9 lower risk)

0.51

Valuation

As of 2025-06-30 (Overview)

Trailing P/E (<15 better)

N/A

Forward P/E (<15 better)

N/A

EV/EBITDA (<8 favorable)

-3.25

EV/Revenue (<3 favorable)

N/A

P/S (TTM) (<3 favorable)

N/A

P/B (<3 favorable)

2.86

Ownership

Retail‑heavy

Source: Overview

Insiders (1–5% typical)

5.98%

Institutions (25–75% balanced)

3.52%

Shares Outstanding

3,192,000

Float

3,007,700

Dividend Yield (2–6% sweet spot)

N/A

Ex‑Dividend Date

N/A

Income & Growth

Profitability: Weak

As of 2025-06-30 (Overview)

Revenue (TTM)

Gross Profit (TTM)

EPS (TTM)

-24.28

Profit Margin (>10% good)

N/A

Operating Margin (TTM) (higher better)

N/A

ROE (TTM) (>15% strong)

-2.74%

EPS YoY (Quarterly) (>10% good)

N/A

Revenue YoY (Quarterly) (>8% good)

N/A

Momentum

Bearish momentum

Value

0.0523

0.0482

Trend

Rising

Signal Cross

No cross

As of

Sep. 12, 2025